InvestSMART

Rhythm Biosciences Limited (ASX: RHY) - Announcements

Current share price for RHY : $0.067 0.001 (1.47%)+

ASX company news and announcements for Rhythm Biosciences Limited (RHY) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Rhythm Biosciences Limited (RHY) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Rhythm Biosciences Limited (RHY), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Rhythm Biosciences Limited (RHY)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$24 Application for quotation of securities - RHY 11 Apr 2025 9:40AM $0.075 $0.067 fallen by 10.67%
$24 Change in substantial holding 8 Apr 2025 10:46AM $0.070 $0.067 fallen by 4.29%
$24 RHY - Results of Meeting 31 Mar 2025 12:15PM $0.080 $0.067 fallen by 16.25%
$24 EGM - Investor Presentation 31 Mar 2025 8:23AM $0.080 $0.067 fallen by 16.25%
$24 RHY Genetype Commercial Sales 19 Mar 2025 9:06AM $0.089 $0.067 fallen by 24.72%
$24 Notification regarding unquoted securities - RHY 18 Mar 2025 2:16PM $0.091 $0.067 fallen by 26.37%
$24 Appointment of Chief Financial Officer 18 Mar 2025 9:06AM $0.085 $0.067 fallen by 21.18%
$24 Notification of cessation of securities - RHY 17 Mar 2025 5:00PM $0.085 $0.067 fallen by 21.18%
$24 RHY Investor Webinar 5 Mar 2025 9:40AM $0.093 $0.067 fallen by 27.96%
$24 RHY - EGM Notice of Meeting and Proxy Form 27 Feb 2025 9:20AM $0.094 $0.067 fallen by 28.72%
$24 Investor Webinar 27 Feb 2025 9:01AM $0.094 $0.067 fallen by 28.72%
$24 Half-Year Financial Report and Appendix 4D 21 Feb 2025 8:39AM $0.093 $0.067 fallen by 27.96%
$24 Becoming a substantial holder 12 Feb 2025 5:13PM $0.090 $0.067 fallen by 25.56%
$24 Genetype Commercial Integration Completion 4 Feb 2025 9:06AM $0.089 $0.067 fallen by 24.72%
$24 Quarterly Activities Report and Appendix 4C - Dec24 23 Jan 2025 9:16AM $0.091 $0.067 fallen by 26.37%
$24 About the Genetype Acquisition 14 Jan 2025 9:16AM $0.084 $0.067 fallen by 20.24%
$24 GTG: GTG completes sale of geneType business and assets 24 Dec 2024 2:01PM $0.083 $0.067 fallen by 19.28%
$24 Completion of Genetype Risk Assessment Portfolio Acquisition 24 Dec 2024 8:56AM $0.081 $0.067 fallen by 17.28%
$24 Notification regarding unquoted securities - RHY 24 Dec 2024 8:20AM $0.081 $0.067 fallen by 17.28%
$24 RHY Acquires Genetype Genetic Risk Assessment Business 23 Dec 2024 9:44AM $0.080 $0.067 fallen by 16.25%
$24 Trading Halt 20 Dec 2024 1:16PM $0.080 $0.067 fallen by 16.25%
$24 Pause in Trading 20 Dec 2024 1:04PM $0.080 $0.067 fallen by 16.25%
$24 Market Update - All End of CY24 Milestones Attained 18 Dec 2024 8:35AM $0.082 $0.067 fallen by 18.29%
$24 Change of Company Auditor 17 Dec 2024 8:38AM $0.083 $0.067 fallen by 19.28%
$24 Change in substantial holding - Otto Buttula 2 Dec 2024 4:35PM $0.087 $0.067 fallen by 22.99%

151 - 175 of 652 results

Page 7 of 27

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.